TickerTalks
Browse all tickers →
TickerTalks›$ELV
ELELV

Elevance Health Inc.

$ELV·$86B·Medical - Healthcare Plans·Healthcare
$392.73-0.5%YTD+12.5%1Y+23.4%
Price updated 8m ago·X counts updated 2d ago
ELELV
$ELVElevance Health Inc.
$392.73-0.47%36 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $ELV on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

36X posts · last 7 days
Sep 11Sep 27
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $ELV's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-29

ELV posts are dominated by Elevra Lithium ($ELV/$ELVR) signing a binding 7+7yr Mangrove Lithium offtake for NAL spodumene (122-144k dmt take-or-pay), which could let ELV focus on supplying North America and avoid China. A single equity-relevant post shows Elevance Health at 6.5% of a portfolio. Loud voices bullish on the lithium offtake catalyst; treat as ticker collision on the health insurer.

Read what X is saying about $ELV

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ELV — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-29

The move is getting stronger, with heavier trading behind it.

Elevance Health: +12% YTD as Q2 EPS $7.45 beat by 20% — reaffirmed FY26 GAAP EPS $20.10 min + adjusted $27.00+.

Elevance Health is the health-insurance major (Anthem, Blue Cross) at $394 with $86B market cap. +12% YTD, +23% TTM as beat cadence expands: Q2 EPS $7.45 vs $6.21 est (+20%), Q1 $12.58 +16%, Q4 2025 $3.33 +7%, Q3 2025 $6.03 +22%.

The tension in one line:

  • Beat cadence elite: four consecutive double-digit beats averaging 16.5% — Elevance is compounding on top of consensus that keeps catching up.
  • Guide reaffirmed with specificity: Sept 10 FY26 GAAP EPS ≥$20.10 (including ~$6.90 unfavorable items) and adjusted $27.00+ with benefit expense ratio 90.2% ±50bps — specific, hard numbers that the market can price.
  • Multiple compressed but reasonable: PE 16.5x TTM, 7.6% FCF yield, PS 0.42x; 2027 analyst EPS $29.57 implies 13.3x forward — reasonable for a durable healthcare-services compounder.

The bull path is Oct 21 Q3 print ($4.66 EPS est) confirming beat cadence plus benefit-expense-ratio holding at 90.2%. The bear path is a Medicare Advantage utilization spike. Elevance is a defensive compounder at a value multiple with visible upside.

What to watch: Oct 21 Q3 print ($4.66 EPS est) — benefit expense ratio vs 90.2% target, Medicare Advantage utilization, and any FY26 guide revision. Continued institutional accumulation. Any regulatory noise on managed-care.

On the calendar: 2026-10-21 — Q3 earnings

Read the AI verdict on $ELV

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Large managed care company providing health insurance and related benefits to ~118 million individuals across commercial, Medicare, and Medicaid segments.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Plans sits in its cycle right now — and what that implies for $ELV.

Medical - Healthcare Plans · Healthcare

Medicaid redeterminations (post-COVID eligibility reviews) have reduced Medicaid enrollment ~15M from peak, improving commercial insurance mix at managed care organizations; Medicare Advantage star ratings and benchmark rate adjustments are the primary 2026 earnings variable. MLR creep from utilization recovery and GLP-1 pharmacy costs are the key margin headwinds.

What this means for $ELV

Direct beneficiary — Large managed care company providing health insurance and related benefits to ~118 million individuals across commercial, Medicare, and Medicaid segments.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+15.9%YTD
+13.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
16.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
7.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
3.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
7.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
12.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
23.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 15, 2026$7.45$6.21+20.0%
Q1 2026Apr 22, 2026$12.58$10.82+16.3%
Q4 2025Jan 28, 2026$3.33$3.10+7.4%
Q3 2025Oct 21, 2025$6.03$4.93+22.3%
Next earningsWed, Oct 21·consensus EPS $4.66

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$50.2B+2.6%18.1%5.3%$8.00$4.1B
Q4 FY25$49.7B+9.5%23.5%1.2%$2.47$-209.0M
Q3 FY25$50.7B+12.3%24.8%3.5%$5.32$775.0M
Q2 FY25$49.8B+14.0%26.3%5.3%$7.72$1.8B

Forward consensus

5-year forecast · up to 15 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$197.5B$192.1B – $202.2B$27.17$25.86 – $28.3414
FY27$201.9B$194.5B – $211.0B$29.57$29.08 – $30.5815
FY28$212.4B$200.2B – $222.1B$33.83$31.98 – $36.4611
FY29$213.1B$205.9B – $220.7B$39.97$38.22 – $41.825
FY30$230.6B$222.8B – $238.8B$46.69$44.65 – $48.855

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.75%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-0.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 216.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.705-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJul 17Ramiro G PeruDirector1.0K sh$366KBuyJul 17Gail BoudreauxCEO2.7K sh$1.0MSellJun 12Ronald W PenczekCAO & Controller369 sh$149KSellJun 11Robert L DixonDirector151 sh$61KSellMay 19Ronald W PenczekCAO & Controller1.5K sh$617K
+ 14 other (10 awards · 3 inkinds · 1 exempt) in window

See when $ELV insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 108-K — Item 7.01: Press release / Reg FD
AI summary

Elevance Health (ELV) reaffirmed full-year 2026 EPS guidance at a minimum of $20.10 GAAP (including ~$6.90 of unfavorable items) and $27.00+ adjusted, alongside a benefit expense ratio target of 90.2% ±50 basis points. The disclosure was made in connection with upcoming investor and analyst meetings. Guidance signals management confidence despite known cost headwinds in its health insurance book.

8-KPress release / Reg FDJun 108-K — Item 7.01: Press release / Reg FD
AI summary

Elevance Health officers reaffirmed full year 2026 shareholders' earnings guidance of at least $19.85 per diluted share (reported, including approximately $6.90 of net unfavorable items) and at least $26.75 per diluted share (adjusted) during investor meetings in the week of June 10, 2026; full year 2026 benefit expense ratio guidance of 90.2% ±50 basis points was also reaffirmed. Guidance reaffirmation is a positive confirmation that Elevance's medical cost trends remain within expectations — a critical data point for managed care investors following sector-wide cost concerns.

8-KShareholder voteMay 138-K — Item 5.07: Shareholder vote
AI summary

Elevance Health held its 2026 Annual Meeting on May 13, 2026, with 194,441,339 shares represented. Three directors were elected to three-year terms ending 2029: Gail K. Boudreaux (177,978,713 for), Robert L. Dixon Jr. (174,098,489 for), and Deanna D. Strable (175,331,822 for). Say-on-pay was approved with 172,363,616 for and 7,240,619 against (~96% approval), and Ernst & Young was ratified as auditor. A shareholder proposal relating to pharmacy benefit manager (PBM) practices was also presented and voted upon at the meeting.

+ 8 other (2 10-Qs · 2 earnings 8-Ks · 2 11-Ks · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Elevance Health (NYSE:ELV) Issues FY 2026 Earnings Guidancedefenseworld.net·9d agoAre Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?zacks.com·13d agoCorient Private Wealth LP Sells 28,940 Shares of Elevance Health, Inc. $ELVdefenseworld.net·14d agoELV or DHR: Which Is the Better Value Stock Right Now?zacks.com·14d agoElevance Health Stock is Moving Higher After FY26 EPS Reaffirmationbenzinga.com·19d ago

More in Medical - Healthcare Plans

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OSCR$UNH$CI$CVS$CLOV$CNC$ALHC$HUM
Voices on X · last 7 days

No standout posts about $ELV on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport